TD Private Client Wealth LLC Has $66,000 Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

TD Private Client Wealth LLC grew its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 39.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,707 shares of the specialty pharmaceutical company’s stock after buying an additional 483 shares during the quarter. TD Private Client Wealth LLC’s holdings in Collegium Pharmaceutical were worth $66,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. nVerses Capital LLC lifted its holdings in shares of Collegium Pharmaceutical by 1,600.0% during the 2nd quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 1,600 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Collegium Pharmaceutical by 124.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 792 shares during the last quarter. CWM LLC lifted its holdings in shares of Collegium Pharmaceutical by 97.5% during the 3rd quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after buying an additional 736 shares during the last quarter. Virtus Fund Advisers LLC acquired a new stake in shares of Collegium Pharmaceutical during the 3rd quarter valued at about $72,000. Finally, AXA S.A. acquired a new stake in shares of Collegium Pharmaceutical during the 2nd quarter valued at about $209,000.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Piper Sandler restated a “neutral” rating and issued a $37.00 target price on shares of Collegium Pharmaceutical in a report on Friday, October 11th. StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Finally, HC Wainwright boosted their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, September 5th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $42.60.

Collegium Pharmaceutical Price Performance

Shares of COLL stock opened at $30.09 on Monday. Collegium Pharmaceutical, Inc. has a 12 month low of $28.75 and a 12 month high of $42.29. The firm has a market cap of $970.40 million, a PE ratio of 12.97 and a beta of 0.80. The stock has a 50 day moving average of $33.24 and a 200-day moving average of $34.38. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.